Skip to main content
Top
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Hepatitis C | Research

Prevalence of hepatitis B and C infection and linkage to care among patients with Non-Communicable Diseases in three rural Rwandan districts: a retrospective cross-sectional study

Authors: Tumusime Musafiri, Innocent Kamali, Casmille Kayihura, Jean de la Paix Gakuru, Francoise Nyirahabihirwe, Esdras Nizeyimana, Pilar Kandamage, Placide Habinshuti, Raymond Sekagarura, Jean Damascene Makuza, Nadine Karema, Janvier Serumondo, Theoneste Ntakirutimana, Jean d’Amour Ndahimana, Dale A. Barnhart

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Introduction

Rwanda’s Hepatitis C elimination campaign has relied on mass screening campaigns. An alternative “micro-elimination” strategy focused on specific populations, such as non-communicable disease (NCD) patients, could be a more efficient approach to identifying patients and linking them to care.

Methods

This retrospective cross-sectional study used routine data collected during a targeted screening campaign among NCD patients in Kirehe, Kayonza, and Burera districts of Rwanda and patients receiving oncology services from the Butaro District Hospital. The campaign used rapid diagnostic tests to screen for Hepatitis B surface antigen (HBsAg) and Hepatitis C antibody (anti-HCV). We reported prevalences and 95% confidence intervals for HBsAg and anti-HCV, assessed for associations between patients’ clinical programs and hepatitis B and C, and reported cascade of care for the two diseases.

Results

Out of 7,603 NCD patients, 3398 (45.9%) self-reported a prior hepatitis screening. Prevalence of HBsAg was 2.0% (95% CI: 1.7%-2.3%) and anti-HCV was 6.7% (95% CI: 6.2%-7.3%). The prevalence of HBsAg was significantly higher among patients < 40 years (2.4%). Increased age was significantly associated with anti-HCV (12.0% among patients ≥ 70 years). Of the 148 individuals who screened positive for HbsAg, 123 had viral load results returned, 101 had detectable viral loads (median viral load: 451 UI/mL), and 12 were linked to care. Of the 507 individuals who screened positive for anti-HCV, 468 had their viral load results returned (median viral load: 1,130,000 UI/mL), 304 had detectable viral loads, and 230 were linked to care.

Conclusion

Anti-HCV prevalence among Rwandan patients with NCD was high, likely due to their older age. NCD-HCV co-infected patients had high HCV viral loads and may be at risk of poor outcomes from hepatitis C. Hepatitis C micro-elimination campaigns among NCD patients are a feasible and acceptable strategy to enhance case detection in this high-prevalence population with elevated viral loads and may support linkage to care for hepatitis C among elderly populations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–8.CrossRefPubMedPubMedCentral Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–8.CrossRefPubMedPubMedCentral
2.
go back to reference Ghany MG, Morgan TR. Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721.CrossRefPubMed Ghany MG, Morgan TR. Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721.CrossRefPubMed
4.
go back to reference Petruzziellorn A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824–40.CrossRef Petruzziellorn A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824–40.CrossRef
5.
go back to reference Nsanzimana S, Penkunas MJ, Liu CY, Sebuhoro D, Ngwije A, Remera E, et al. Effectiveness of direct-acting antivirals for the treatment of chronic hepatitis C in Rwanda: a retrospective study. Clin Infect Dis. 2020;110(8):2019. Nsanzimana S, Penkunas MJ, Liu CY, Sebuhoro D, Ngwije A, Remera E, et al. Effectiveness of direct-acting antivirals for the treatment of chronic hepatitis C in Rwanda: a retrospective study. Clin Infect Dis. 2020;110(8):2019.
7.
go back to reference Suk-Fong LA. Hepatitis B treatment: what we know now and what remains to be researched. Hepatol Commun. 2019;3(1):8–19.ADSCrossRef Suk-Fong LA. Hepatitis B treatment: what we know now and what remains to be researched. Hepatol Commun. 2019;3(1):8–19.ADSCrossRef
8.
go back to reference Mauss S, Pol S, Buti M, Duffell E, Gore C, Lazarus JV, et al. Late presentation of chronic viral hepatitis for medical care: a consensus definition. BMC Med. 2017;15(1):1–5.CrossRef Mauss S, Pol S, Buti M, Duffell E, Gore C, Lazarus JV, et al. Late presentation of chronic viral hepatitis for medical care: a consensus definition. BMC Med. 2017;15(1):1–5.CrossRef
10.
go back to reference Umutesi J, Simmons B, Makuza JD, Dushimiyimana D, Mbituyumuremyi A, Uwimana JM, et al. Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda. BMC Infect Dis. 2017;17(1):1–7.CrossRef Umutesi J, Simmons B, Makuza JD, Dushimiyimana D, Mbituyumuremyi A, Uwimana JM, et al. Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda. BMC Infect Dis. 2017;17(1):1–7.CrossRef
11.
go back to reference Umutesi J, Liu CY, Penkunas MJ, Makuza JD, Ntihabose CK, Umuraza S, et al. Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population. BMJ Open. 2019;9(7):1–8.CrossRef Umutesi J, Liu CY, Penkunas MJ, Makuza JD, Ntihabose CK, Umuraza S, et al. Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population. BMJ Open. 2019;9(7):1–8.CrossRef
14.
go back to reference Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination – A path to global elimination of hepatitis C. J Hepatol. 2017;67:665–6 Elsevier B.V..CrossRefPubMed Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination – A path to global elimination of hepatitis C. J Hepatol. 2017;67:665–6 Elsevier B.V..CrossRefPubMed
15.
go back to reference Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018;38(3):181–92.CrossRefPubMed Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018;38(3):181–92.CrossRefPubMed
16.
go back to reference Makuza JD, Rwema JOT, Ntihabose CK, Dushimiyimana D, Umutesi J, Nisingizwe MP, et al. Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda. BMC Infect Dis. 2019;19(1):1–10.CrossRef Makuza JD, Rwema JOT, Ntihabose CK, Dushimiyimana D, Umutesi J, Nisingizwe MP, et al. Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda. BMC Infect Dis. 2019;19(1):1–10.CrossRef
17.
go back to reference Nahimana M, Nyandwi A, Muhimpundu MA, Olu O, Condo JU, Rusanganwa A, et al. A population-based national estimate of the prevalence and risk factors associated with hypertension in Rwanda: implications for prevention and control. 2018. p. 1–11. Nahimana M, Nyandwi A, Muhimpundu MA, Olu O, Condo JU, Rusanganwa A, et al. A population-based national estimate of the prevalence and risk factors associated with hypertension in Rwanda: implications for prevention and control. 2018. p. 1–11.
18.
go back to reference Iradukunda PG, Habyarimana T, Niyonzima FN, Uwitonze AY, Mpunga T. Risk factors associated with hepatitis B and C in rural population of Burera district, Rwanda. Pan Afr Med J. 2020;35:1–10. Iradukunda PG, Habyarimana T, Niyonzima FN, Uwitonze AY, Mpunga T. Risk factors associated with hepatitis B and C in rural population of Burera district, Rwanda. Pan Afr Med J. 2020;35:1–10.
19.
go back to reference Lecube A, Hernández C, Genescà J, Simó R. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care. 2006;29(5):1140–9.CrossRefPubMed Lecube A, Hernández C, Genescà J, Simó R. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care. 2006;29(5):1140–9.CrossRefPubMed
20.
go back to reference Chen WJ, Chen C; Group REVEALS. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases : a community-based long-term prospective study. J Infect Dis. 2012;206:469–77. Chen WJ, Chen C; Group REVEALS. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases : a community-based long-term prospective study. J Infect Dis. 2012;206:469–77.
21.
go back to reference Rossi C, Raboud J, Walmsley S, Cooper C, Antoniou T, Burchell AN, et al. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infect Dis. 2017;17(1):1–10.CrossRef Rossi C, Raboud J, Walmsley S, Cooper C, Antoniou T, Burchell AN, et al. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infect Dis. 2017;17(1):1–10.CrossRef
22.
go back to reference Mutagoma M, Balisanga H, Sebuhoro D, Mbituyumuremyi A, Remera E, Malamba SS, et al. Hepatitis C virus and HIV co-infection among pregnant women in Rwanda. 2017. p. 4–9. Mutagoma M, Balisanga H, Sebuhoro D, Mbituyumuremyi A, Remera E, Malamba SS, et al. Hepatitis C virus and HIV co-infection among pregnant women in Rwanda. 2017. p. 4–9.
23.
go back to reference Umutesi J, Klett- C, Nsanzimana S, Krause G. sectional study of chronic hepatitis B virus infection in Rwandan risk groups: unexpected findings on prevalence and its determinants. 2021. Umutesi J, Klett- C, Nsanzimana S, Krause G. sectional study of chronic hepatitis B virus infection in Rwandan risk groups: unexpected findings on prevalence and its determinants. 2021.
25.
go back to reference Marcuccilli F, Chevaliez S, Muller T, Colagrossi L, Abbondanza G, Beyser K, et al. Multicenter evaluation of the cepheid xpert® hbv viral load test. Diagnostics. 2021;11(2):1–7.CrossRef Marcuccilli F, Chevaliez S, Muller T, Colagrossi L, Abbondanza G, Beyser K, et al. Multicenter evaluation of the cepheid xpert® hbv viral load test. Diagnostics. 2021;11(2):1–7.CrossRef
26.
go back to reference Shenge JA, Osiowy C. Rapid diagnostics for hepatitis B and C viruses in low- and middle-income countries. Front Virol. 2021;1(October):1–12. Shenge JA, Osiowy C. Rapid diagnostics for hepatitis B and C viruses in low- and middle-income countries. Front Virol. 2021;1(October):1–12.
28.
go back to reference Health MOF. Ministry of health national reference laboratory biological sample transportation within the national laboratory. 2012. Health MOF. Ministry of health national reference laboratory biological sample transportation within the national laboratory. 2012.
30.
go back to reference Rwanda Biomedical Center (RBC). Rwanda Population-Based HIV Impact Assessment. (RPHIA) 2018-2019: Final Report. Kigali: RBC; 2020. Rwanda Biomedical Center (RBC). Rwanda Population-Based HIV Impact Assessment. (RPHIA) 2018-2019: Final Report. Kigali: RBC; 2020.
31.
go back to reference Nisingizwe MP, Makuza JD, Janjua NZ, Bansback N, Hedt-Gauthier B, Serumondo J, et al. The cascade of care for hepatitis C treatment in Rwanda: a retrospective cohort study of the 2017–2019 mass screening and treatment campaign. Viruses. 2023;15(3):661.CrossRefPubMedPubMedCentral Nisingizwe MP, Makuza JD, Janjua NZ, Bansback N, Hedt-Gauthier B, Serumondo J, et al. The cascade of care for hepatitis C treatment in Rwanda: a retrospective cohort study of the 2017–2019 mass screening and treatment campaign. Viruses. 2023;15(3):661.CrossRefPubMedPubMedCentral
32.
go back to reference Carvalho-Gomes Â, Cubells A, Pallarés C, Hontangas V, Conde I, Di MT, et al. A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area. PLoS ONE. 2020;15(2):1–14.CrossRef Carvalho-Gomes Â, Cubells A, Pallarés C, Hontangas V, Conde I, Di MT, et al. A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area. PLoS ONE. 2020;15(2):1–14.CrossRef
33.
go back to reference Basaranoglu M, Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol. 2011;17(36):4055–62.CrossRefPubMedPubMedCentral Basaranoglu M, Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol. 2011;17(36):4055–62.CrossRefPubMedPubMedCentral
34.
go back to reference Makuza JD, Liu CY, Ntihabose CK, Dushimiyimana D, Umuraza S, Nisingizwe MP, et al. Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program. 2019. p. 1–10. Makuza JD, Liu CY, Ntihabose CK, Dushimiyimana D, Umuraza S, Nisingizwe MP, et al. Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program. 2019. p. 1–10.
35.
go back to reference Pierre G, Iradukunda PG, Tumusiime M, Harelimana JDD, Rutayisire G, Nyakatswau ST, et al. Medical laboratory professional’s week in Rwanda: a field report from the Simbi and Maraba communities. Int J Community Med Public Heal. 2021;8(5):2111.CrossRef Pierre G, Iradukunda PG, Tumusiime M, Harelimana JDD, Rutayisire G, Nyakatswau ST, et al. Medical laboratory professional’s week in Rwanda: a field report from the Simbi and Maraba communities. Int J Community Med Public Heal. 2021;8(5):2111.CrossRef
36.
go back to reference Id IK, Barnhart DA, Ndahimana A, Noor K, Mumporeze J, De J, et al. Prevalence and associated risk factors for hepatitis B and C viruses among refugee populations living in Mahama, Rwanda: a cross-sectional study. 2021. p. 1–14. Id IK, Barnhart DA, Ndahimana A, Noor K, Mumporeze J, De J, et al. Prevalence and associated risk factors for hepatitis B and C viruses among refugee populations living in Mahama, Rwanda: a cross-sectional study. 2021. p. 1–14.
37.
go back to reference Hcv S, Level RNA, Fibrosis L, Hélène M, Chanoine N, Paradis V, et al. Insulin resistance in chronic hepatitis C: association with genotypes. 2008. p. 416–23. Hcv S, Level RNA, Fibrosis L, Hélène M, Chanoine N, Paradis V, et al. Insulin resistance in chronic hepatitis C: association with genotypes. 2008. p. 416–23.
40.
go back to reference Kamali I, Barnhart DA, Nyirahabihirwe F, de la Paix Gakuru J, Uwase M, Nizeyumuremyi E, Walker S, Mazimpaka C, de Dieu Gatete J, Makuza JD, Serumondo J, Kateera F, d'Amour Ndahimana J. Initiation of hepatitis C treatment in two rural Rwandan districts: a mobile clinic approach. BMC Infect Dis. 2021;21(1):220. https://doi.org/10.1186/s12879-021-05920-3. Kamali I, Barnhart DA, Nyirahabihirwe F, de la Paix Gakuru J, Uwase M, Nizeyumuremyi E, Walker S, Mazimpaka C, de Dieu Gatete J, Makuza JD, Serumondo J, Kateera F, d'Amour Ndahimana J. Initiation of hepatitis C treatment in two rural Rwandan districts: a mobile clinic approach. BMC Infect Dis. 2021;21(1):220. https://​doi.​org/​10.​1186/​s12879-021-05920-3.
Metadata
Title
Prevalence of hepatitis B and C infection and linkage to care among patients with Non-Communicable Diseases in three rural Rwandan districts: a retrospective cross-sectional study
Authors
Tumusime Musafiri
Innocent Kamali
Casmille Kayihura
Jean de la Paix Gakuru
Francoise Nyirahabihirwe
Esdras Nizeyimana
Pilar Kandamage
Placide Habinshuti
Raymond Sekagarura
Jean Damascene Makuza
Nadine Karema
Janvier Serumondo
Theoneste Ntakirutimana
Jean d’Amour Ndahimana
Dale A. Barnhart
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08678-y

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine